Security key
00461U105
Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS)
CUSIP: 00461U105
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock, $0.00001 par value
- Total 13F shares
- 155,965
- Total 13F value
- $825,055
- Share change
- -22,338
- SEC-reported price per share
- $5.29
- Number of holders
- 3
- Value change
- -$118,168
- Number of buys
- 1
- Number of sells
- 1
- Shares outstanding
- 138,752,791
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
3
Top holders
3
ACRS full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
Aclaris Therapeutics, Inc. SEC filings
Aclaris Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 00461U105
Recent filing periods:
Ownership snapshot
Top reported holders of ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BML Investment Partners, ...
Disclosed value leader
BML Capital Management, LLC
Comparable rows
15/15
Latest evidence
23 Apr 2026
13D/G
13F
Lead comparable stake: 9.9%
13D/G row: BML Investment Partners, L.P.
Showing 1-6 of 15 holder rows.
Quick read
BML Investment Partners, L.P. leads the comparable SEC ownership view at 9.9%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BML Investment Partners, L.P.'s linked filing trail.
Comparable ownership
Top 5
BML Investment Partners, L.P.
9.9%
Bonita Biotech (HK) Ltd
9.4%
Deep Track Capital, LP
7%
RA CAPITAL MANAGEMENT, L.P.
6.3%
BlackRock, Inc.
6.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BML Investment Partners, L.P. |
13D/G
|
9.9%
|
$52,312,500
13,950,000 shares
|
-$1,125,000 | 23 Apr 2026 |
| Bonita Biotech (HK) Ltd |
13D/G
Biosion, Inc.
|
9.4%
|
$33,944,003
11,281,950 shares
|
$0 | 09 Dec 2025 |
| Deep Track Capital, LP |
13F
13D/G
Company
|
7%
from 13D/G
|
$35,043,750
9,345,000 shares
|
— | 31 Mar 2026 |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
13F
Company
|
6.3%
|
$28,600,144
7,626,705 shares
|
$0 | 31 Mar 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
6.2%
from 13D/G
|
$27,776,494
7,407,065 shares
|
— | 31 Mar 2026 |
| Adage Capital Management, L.P. |
13D/G
|
4.9%
|
$10,028,474
5,278,144 shares
|
-$5,554,080 | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
3
Shares
155,965
Rows available
3
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
135
Q2 2026 holders
3
Holder diff
-132
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend